| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Anne-Sophie Rigaud, Gabriel André, Bruno Vellas, Jacques Touchon, Jean-Jacques Pere, Yolande Loria-Kanz. [Oestro-progestagen treatment combined with rivastigmine in menopausal women suffering from Alzheimer's disease. The results of a 28-weeks controlled study]. Presse medicale (Paris, France : 1983). vol 32. issue 35. 2003-12-24. PMID:14631268. |
to compare the efficacy on cognitive function of the combination of hormone replacement therapy with rivastigmine, acetylcholinesterase inhibitor, in menopausal women suffering from mild to moderately severe alzheimer's disease. |
2003-12-24 |
2023-08-12 |
Not clear |
| Harry M Greenblatt, Hay Dvir, Israel Silman, Joel L Sussma. Acetylcholinesterase: a multifaceted target for structure-based drug design of anticholinesterase agents for the treatment of Alzheimer's disease. Journal of molecular neuroscience : MN. vol 20. issue 3. 2003-12-23. PMID:14501022. |
acetylcholinesterase: a multifaceted target for structure-based drug design of anticholinesterase agents for the treatment of alzheimer's disease. |
2003-12-23 |
2023-08-12 |
Not clear |
| Harry M Greenblatt, Hay Dvir, Israel Silman, Joel L Sussma. Acetylcholinesterase: a multifaceted target for structure-based drug design of anticholinesterase agents for the treatment of Alzheimer's disease. Journal of molecular neuroscience : MN. vol 20. issue 3. 2003-12-23. PMID:14501022. |
the structure of torpedo californica acetylcholinesterase is examined in complex with several inhibitors that are either in use or under development for treating alzheimer's disease. |
2003-12-23 |
2023-08-12 |
Not clear |
| Irene Hegeman Richard, Anne Wallace Justus, Nigel H Greig, Frederick Marshall, Roger Kurla. Worsening of motor function and mood in a patient with Parkinson's disease after pharmacologic challenge with oral rivastigmine. Clinical neuropharmacology. vol 25. issue 6. 2003-12-16. PMID:12469000. |
clinicians are faced with the dilemma as to whether or not to treat patients with pd with the acetylcholinesterase inhibitors that are currently approved for use in alzheimer's disease (ad) and that have shown promise in clinical trials of dementia with lewy bodies (dlb). |
2003-12-16 |
2023-08-12 |
Not clear |
| Narihiro Toda, Keiko Tago, Shinji Marumoto, Kazuko Takami, Mayuko Ori, Naho Yamada, Kazuo Koyama, Shunji Naruto, Kazumi Abe, Reina Yamazaki, Takao Hara, Atsushi Aoyagi, Yasuyuki Abe, Tsugio Kaneko, Hiroshi Koge. Design, synthesis and structure-activity relationships of dual inhibitors of acetylcholinesterase and serotonin transporter as potential agents for Alzheimer's disease. Bioorganic & medicinal chemistry. vol 11. issue 9. 2003-12-12. PMID:12670645. |
design, synthesis and structure-activity relationships of dual inhibitors of acetylcholinesterase and serotonin transporter as potential agents for alzheimer's disease. |
2003-12-12 |
2023-08-12 |
mouse |
| Narihiro Toda, Keiko Tago, Shinji Marumoto, Kazuko Takami, Mayuko Ori, Naho Yamada, Kazuo Koyama, Shunji Naruto, Kazumi Abe, Reina Yamazaki, Takao Hara, Atsushi Aoyagi, Yasuyuki Abe, Tsugio Kaneko, Hiroshi Koge. Design, synthesis and structure-activity relationships of dual inhibitors of acetylcholinesterase and serotonin transporter as potential agents for Alzheimer's disease. Bioorganic & medicinal chemistry. vol 11. issue 9. 2003-12-12. PMID:12670645. |
we have designed and synthesized a dual inhibitor of acetylcholinesterase (ache) and serotonin transporter (sert) as a novel class of treatment drugs for alzheimer's disease on the basis of a hypothetical model of the ache active site. |
2003-12-12 |
2023-08-12 |
mouse |
| Min Wu, Samuel S Newton, Joshua B Atkins, Changqing Xu, Ronald S Duman, Meenakshi Alrej. Acetylcholinesterase inhibitors activate septohippocampal GABAergic neurons via muscarinic but not nicotinic receptors. The Journal of pharmacology and experimental therapeutics. vol 307. issue 2. 2003-12-10. PMID:12966162. |
acetylcholinesterase (ache) inhibitors, which increase synaptic levels of available acetylcholine (ach) by preventing its degradation, are the most extensively prescribed drugs for the treatment of alzheimer's disease. |
2003-12-10 |
2023-08-12 |
rat |
| A Bianchetti, R Rozzini, M Trabucch. Effects of acetyl-L-carnitine in Alzheimer's disease patients unresponsive to acetylcholinesterase inhibitors. Current medical research and opinion. vol 19. issue 4. 2003-12-03. PMID:12841930. |
effects of acetyl-l-carnitine in alzheimer's disease patients unresponsive to acetylcholinesterase inhibitors. |
2003-12-03 |
2023-08-12 |
Not clear |
| Federico A Dajas-Bailador, Kaisa Heimala, Susan Wonnacot. The allosteric potentiation of nicotinic acetylcholine receptors by galantamine is transduced into cellular responses in neurons: Ca2+ signals and neurotransmitter release. Molecular pharmacology. vol 64. issue 5. 2003-11-25. PMID:14573772. |
of these, the acetylcholinesterase inhibitor and alzheimer drug galantamine represents the prototypical allosteric ligand, based on its potentiation of nachr-evoked single-channel and whole-cell currents. |
2003-11-25 |
2023-08-12 |
Not clear |
| A Turon-Estrada, S López-Pousa, E Gelada-Batlle, J Garre-Olmo, M Lozano-Gallego, M Hernández-Ferràndiz, C Fajardo-Tibau, V Morante-Muñoz, J Vilalta-Franc. [Tolerance and adverse events of treatment with acetylcholinesterase inhibitors in a clinical sample of patients with very slight and mild Alzheimer s disease over a six-month period]. Revista de neurologia. vol 36. issue 5. 2003-11-18. PMID:12640593. |
[tolerance and adverse events of treatment with acetylcholinesterase inhibitors in a clinical sample of patients with very slight and mild alzheimer s disease over a six-month period]. |
2003-11-18 |
2023-08-12 |
Not clear |
| A Turon-Estrada, S López-Pousa, E Gelada-Batlle, J Garre-Olmo, M Lozano-Gallego, M Hernández-Ferràndiz, C Fajardo-Tibau, V Morante-Muñoz, J Vilalta-Franc. [Tolerance and adverse events of treatment with acetylcholinesterase inhibitors in a clinical sample of patients with very slight and mild Alzheimer s disease over a six-month period]. Revista de neurologia. vol 36. issue 5. 2003-11-18. PMID:12640593. |
at present acetylcholinesterase inhibitors (achei) are used in the treatment of the cognitive deterioration associated with alzheimer s disease (ad). |
2003-11-18 |
2023-08-12 |
Not clear |
| T Rees, P I Hammond, H Soreq, S Younkin, S Brimijoi. Acetylcholinesterase promotes beta-amyloid plaques in cerebral cortex. Neurobiology of aging. vol 24. issue 6. 2003-10-29. PMID:12927760. |
studies in vitro have suggested that acetylcholinesterase (ache) may interact with beta-amyloid to promote deposition of amyloid plaques in the brain of patients with alzheimer's disease. |
2003-10-29 |
2023-08-12 |
mouse |
| Kaj Blennow, Harald Hampe. CSF markers for incipient Alzheimer's disease. The Lancet. Neurology. vol 2. issue 10. 2003-10-23. PMID:14505582. |
early diagnosis of alzheimer's disease (ad) is needed to initiate symptomatic treatment with acetylcholinesterase inhibitors, and will be of even greater significance if drugs aimed at slowing down the degenerative process, such as vaccination regimes and beta-secretase and gamma-secretase inhibitors, prove to affect ad pathology and to have clinical effect. |
2003-10-23 |
2023-08-12 |
Not clear |
| Matthew G Cottingham, Jan L A Voskuil, David J T Vau. The intact human acetylcholinesterase C-terminal oligomerization domain is alpha-helical in situ and in isolation, but a shorter fragment forms beta-sheet-rich amyloid fibrils and protofibrillar oligomers. Biochemistry. vol 42. issue 36. 2003-10-14. PMID:12962511. |
a 14-residue fragment of the c-terminal oligomerization domain, or t-peptide, of human acetylcholinesterase (ache) shares sequence homology with the amyloid-beta peptide implicated in alzheimer's disease and can spontaneously self-assemble into classical amyloid fibrils under physiological conditions [greenfield, s. a., and vaux, d. j. |
2003-10-14 |
2023-08-12 |
human |
| Nicola Pelizzi, Paola Puccini, Benedetta Riccardi, Daniela Acerbi, Silvia Catinell. Characterization of Ganstigmine metabolites in hepatocytes by low- and high-resolution mass spectrometry coupled with liquid chromatography. Rapid communications in mass spectrometry : RCM. vol 17. issue 15. 2003-10-01. PMID:12872272. |
in order to deepen the understanding of the metabolism of ganstigmine, a new acetylcholinesterase inhibitor under evaluation for the treatment of alzheimer's disease, samples obtained by incubating the drug with female rat hepatocytes were investigated by low-resolution liquid chromatography/tandem mass spectrometry (lc/ms/ms). |
2003-10-01 |
2023-08-12 |
rat |
| Yuki Takada, Atsushi Yonezawa, Toshiaki Kume, Hiroshi Katsuki, Shuji Kaneko, Hachiro Sugimoto, Akinori Akaik. Nicotinic acetylcholine receptor-mediated neuroprotection by donepezil against glutamate neurotoxicity in rat cortical neurons. The Journal of pharmacology and experimental therapeutics. vol 306. issue 2. 2003-08-28. PMID:12734391. |
donepezil is a potent and selective acetylcholinesterase (ache) inhibitor developed for the treatment of alzheimer's disease. |
2003-08-28 |
2023-08-12 |
rat |
| Edgar Luttmann, Elmar Linnemann, Gregor Fel. Galanthamine as bis-functional ligand for the acetylcholinesterase. Journal of molecular modeling. vol 8. issue 6. 2003-08-18. PMID:12140604. |
acetylcholinesterase plays a key role in the development of alzheimer's disease as this enzyme is responsible for cleavage of the neurotransmitter acetylcholine, and, according to recent investigations, also promotes aggregation of beta-amyloid peptides, which causes plaque formation in synaptic areas. |
2003-08-18 |
2023-08-12 |
Not clear |
| Tina M Rees, Stephen Brimijoi. The role of acetylcholinesterase in the pathogenesis of Alzheimer's disease. Drugs of today (Barcelona, Spain : 1998). vol 39. issue 1. 2003-08-01. PMID:12669110. |
the role of acetylcholinesterase in the pathogenesis of alzheimer's disease. |
2003-08-01 |
2023-08-12 |
Not clear |
| Tina M Rees, Stephen Brimijoi. The role of acetylcholinesterase in the pathogenesis of Alzheimer's disease. Drugs of today (Barcelona, Spain : 1998). vol 39. issue 1. 2003-08-01. PMID:12669110. |
treatment of alzheimer's disease has been dominated by the use of acetylcholinesterase (ache) inhibitors. |
2003-08-01 |
2023-08-12 |
Not clear |
| Eiichi Katada, Koichi Sato, Akira Sawaki, Yasuaki Dohi, Ryuzo Ueda, Kosei Ojik. Long-term effects of donepezil on P300 auditory event-related potentials in patients with Alzheimer's disease. Journal of geriatric psychiatry and neurology. vol 16. issue 1. 2003-07-16. PMID:12641372. |
we investigated clinical significance of the components of auditory p300 erps, in comparison with neuropsychologic tests including the mini-mental state examination and the japanese version of the alzheimer's disease assessment scale-cognitive subscale (adas-j cog), for evaluating of the effect of donepezil (dpz) (5 mg daily for 6 months), an acetylcholinesterase inhibitor, in patients with alzheimer's disease (ad). |
2003-07-16 |
2023-08-12 |
Not clear |